Investor Stock List
Ranked #2,143 of 8,699 institutional investors

Redmile Group, LLC

Larkspur, CA

$1.16B
US stock portfolio at live prices · today +$5.6M (+0.48%)
Market closed. Prices as of Nov 20, 8:11 AM ET
Value at quarter end (Q3 2026)
$1.37B
Change from Q2 2026
−$123.3M (−8.28%)
Positions
41 · 5 new, 0 sold out
Filed
Nov 16, 2026

Not counted in the ranking: none$24.3M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
KRYS 14.3%SRRK 13.1%NRIX 9.24%STOK 8.96%IMNM 6.23%
StockSharesValue, live% of portfoliovs Q2 2026
KRYS Krystal Biotech, Inc.527,684$167M14.3%Reduced −17%
SRRK Scholar Rock Holding Corporation3,033,962$153M13.1%Reduced −30%
NRIX Nurix Therapeutics, Inc.7,901,085$107M9.24%Added +94%
STOK Stoke Therapeutics, Inc.3,869,028$104M8.96%Reduced −2%
IMNM Immunome, Inc.4,363,064$72.5M6.23%Reduced −11%
ABSI Absci Corporation6,671,377$54.4M4.68%Reduced −1%
SLN Silence Therapeutics plc2,460,894$48.8M4.19%Added +14%
ANNX Annexon, Inc.14,278,075$48.7M4.19%Added +20%
ETRA Electra Therapeutics, Inc.5,430,918$48.6M4.17%New
RGNX REGENXBIO Inc.5,048,502$36.2M3.12%Added +16%
NGNE Neurogene Inc.1,562,199$35.8M3.08%Added +11%
STTK Shattuck Labs, Inc.5,086,990$23.1M1.99%Reduced −26%
BEAM Beam Therapeutics Inc.1,061,782$22.2M1.91%Reduced −9%
ATTO Attovia Therapeutics, Inc.1,163,587$18.1M1.56%New
ZYME Zymeworks Inc.491,654$13.2M1.14%Unchanged
FATE Fate Therapeutics, Inc.12,872,946$13.0M1.12%Unchanged
SLDB Solid Biosciences Inc.1,944,342$12.5M1.08%Reduced −0%
BMRN BioMarin Pharmaceutical Inc.189,538$11.6M1.00%Reduced −29%
NUVB Nuvation Bio Inc.3,031,009$11.5M0.99%Unchanged
ADRX ADARx Pharmaceuticals, Inc.769,345$10.9M0.94%New
AURA Aura Biosciences, Inc.1,552,479$10.8M0.93%Reduced −7%
OBX Obsidian Therapeutics, Inc.833,157$10.1M0.87%New
IDYA IDEAYA Biosciences, Inc.381,319$10.0M0.86%Reduced −40%
CBLL Ceribell Inc386,786$10.0M0.86%Unchanged
AGMB AgomAb Therapeutics NV1,740,230$9.8M0.84%Reduced −36%
CLYM Climb Bio Inc974,489$9.0M0.78%Reduced −21%
CLDX Celldex Therapeutics, Inc.321,770$9.0M0.77%Reduced −26%
COGT Cogent Biosciences, Inc.296,606$8.2M0.71%Reduced −41%
ALXO ALX Oncology Holdings Inc.7,185,263$7.3M0.63%Reduced −3%
XENE Xenon Pharmaceuticals Inc.191,036$7.2M0.62%Reduced −17%
ODTX Odyssey Therapeutics, Inc.374,510$6.9M0.59%Reduced −12%
INSM Insmed Incorporated42,902$6.2M0.53%Reduced −16%
PRME Prime Medicine, Inc.1,146,860$4.4M0.38%Reduced −17%
ATRA Atara Biotherapeutics, Inc.636,852$4.0M0.35%Added +44%
DBVT DBV Technologies S.A.373,417$3.5M0.30%Reduced −9%
EPRX Eupraxia Pharmaceuticals Inc.519,881$3.2M0.27%Reduced −15%
ORIC ORIC Pharmaceuticals, Inc.292,817$2.3M0.19%Reduced −19%
ARDX Ardelyx, Inc.523,870$1.6M0.14%Reduced −18%
OCUL Ocular Therapeutix, Inc.243,954$1.4M0.12%New
IVVD Invivyd, Inc.2,285,320$1.0M<0.1%Reduced −12%
PLRX Pliant Therapeutics, Inc.772,126$479K<0.1%Unchanged